JD Health International Inc. (JD Health) filed its Monthly Return for Equity Issuer with Hong Kong Exchanges and Clearing on 5 November 2026, covering movements up to 31 October 2026. Key disclosures are as follows:

1. Authorised Capital – Authorised ordinary shares remained unchanged at 100.00 billion, with a par value of USD 0.0000005 each, keeping total authorised capital at USD 50,000.

2. Issued Shares and Treasury Position – Issued shares (excluding treasury) stood at 3.19 billion, identical to the prior month. – JD Health held no treasury shares, and there were no share repurchases or cancellations during the period. – The company reaffirmed compliance with the Main Board’s minimum public-float threshold of 25%.

3. Equity Incentive Schemes – Pre-IPO ESOP: Outstanding options declined by 28,467 to 9.40 million, reflecting cancellations, lapses and other adjustments. No new shares were issued; exercised options were settled with existing shares held in trust, resulting in negligible cash proceeds of USD 0.01. – Post-IPO Share Option Scheme: No options are currently outstanding. The plan retains capacity for up to 312.71 million new shares. – Post-IPO Share Award Scheme: 13.48 million shares remain available for future awards; there were no issuances or transfers in October.

4. Overall Capital Movements – Total issued share count and treasury-share balance were unchanged. – No warrants, convertible securities or other equity instruments were issued, converted or redeemed during the month.

JD Health’s equity structure therefore remained stable through October 2026, with adequate headroom under its post-IPO incentive schemes and continued adherence to Hong Kong listing requirements on public float.